company background image
ECQ

PharmAust DB:ECQ Stock Report

Last Price

€0.046

Market Cap

€16.8m

7D

31.4%

1Y

-27.0%

Updated

11 Jan, 2023

Data

Company Financials

ECQ Stock Overview

PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally.

ECQ fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

PharmAust Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PharmAust
Historical stock prices
Current Share PriceAU$0.046
52 Week HighAU$0.066
52 Week LowAU$0.032
Beta0.59
1 Month Change22.67%
3 Month Change10.84%
1 Year Change-26.98%
3 Year Change-5.15%
5 Year Change27.78%
Change since IPO-95.00%

Recent News & Updates

Recent updates

Shareholder Returns

ECQDE PharmaceuticalsDE Market
7D31.4%6.6%4.3%
1Y-27.0%-2.4%-16.4%

Return vs Industry: ECQ underperformed the German Pharmaceuticals industry which returned -2.4% over the past year.

Return vs Market: ECQ underperformed the German Market which returned -16.4% over the past year.

Price Volatility

Is ECQ's price volatile compared to industry and market?
ECQ volatility
ECQ Average Weekly Movement10.2%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement5.2%
10% most volatile stocks in DE Market10.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: ECQ is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ECQ's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2000n/aRoger Astonhttps://www.pharmaust.com

PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer.

PharmAust Limited Fundamentals Summary

How do PharmAust's earnings and revenue compare to its market cap?
ECQ fundamental statistics
Market Cap€16.84m
Earnings (TTM)-€1.10m
Revenue (TTM)€2.89m

5.8x

P/S Ratio

-15.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ECQ income statement (TTM)
RevenueAU$4.51m
Cost of RevenueAU$314.34k
Gross ProfitAU$4.20m
Other ExpensesAU$5.90m
Earnings-AU$1.71m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.0053
Gross Margin93.03%
Net Profit Margin-37.87%
Debt/Equity Ratio2.7%

How did ECQ perform over the long term?

See historical performance and comparison